Zika vaccine for women of childbearing age unlikely before 2020, WHO says

An article by FiercePharma
February 7, 2017
Since Inovio became the first to test a Zika vaccine in humans, several government agencies and Big Pharmas have either entered the clinic or embarked on the quest. Despite the enormous effort, though, a vaccine for women of childbearing age may not be available before 2020, the World Health Organization estimates.
Margaret Chan, director-general of WHO, made the comment in a piece published one year after she declared Zika as a public health emergency of international concern. The agency lifted that warning level last November, stressing that a “robust longer-term” approach was warranted.
Inovio’s candidate, dubbed GLS-5700, is currently in phase 1, with a second round involving 160 participants underway in Puerto Rico. The National Institutes of Health enrolled 80 volunteers to test its candidate last August and planned to move into phase 2 in early 2017. The most recent group to enter the clinic was the Walter Reed Army Institute of Research, which started human trials of a Zika purified inactivated virus vaccine last November.
The potential $1 billion market and public health benefits have also attracted attention from Big Pharmas around the globe. Sanofi, with a $43 million grant from the Biomedical Advanced Research and Development Authority, is working with the U.S. Army’s Walter Reed and Brazil’s vaccine research institute Fiocruz on the ZPIV candidate. GlaxoSmithKline, from its vaccine R&D hub in Rockville, Maryland, has entered into a collaboration with the NIH to develop self-amplifying mRNA technology for usage in a Zika vaccine.
Find more information here